Fintel reports that on November 18, 2024, Jefferies initiated coverage of Erasca (NasdaqGS:ERAS) with a Buy recommendation.

and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced clinical progress for naporafenib and preclinical execution across the company’s RAS targeting ...

In NF1, many of these medications work by blocking a specific cell signaling pathway called Ras/MAPK that is hyperactive in cells that have lost NF1 function due to gene mutation. When this signaling ...

and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter ended September 30 ...

In the search for the cause of CPAM, the research team pursued the following hypothesis: Variants in cancer-associated genes of the so-called RAS-MAPK signaling pathway, which occur in the lung ...

Erasca, Inc. ( (ERAS) ) has released its Q3 earnings. Here is a breakdown of the information Erasca, Inc. presented to its investors. Erasca, ...

These findings could pave the way for new treatment approaches for cancers driven by RAS mutations. Researchers at the ...

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, ...

Positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort bolsters conviction in ongoing SEACRAFT-2 registrational trial; Stage 1 ...

We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was ...

We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was ...